Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

The company announced Thursday that participants taking 12 milligrams of the drug lost an average of 71.2 lbs after 16 months ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.